Business Context and Reporting Period
This Form 8-K is a current report filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals Inc in metadata) on June 13, 2017, covering events occurring on June 13 and June 14, 2017. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Capital Structure
- Capital Raise: Completed a public offering of common stock, Series B Convertible Preferred Stock, and warrants on June 14, 2017.
- Gross Proceeds: $10.0 million.
- Net Proceeds: Approximately $8.8 million after deducting placement agent fees and estimated offering expenses.
- Series B Preferred Stock: Convertible into common shares at the holder's option, subject to a 4.99% beneficial ownership limitation (increasable to 9.99%). No voting rights except for specific protective provisions. No dividends unless declared.
- Liquidity Status: The filing does not provide specific cash balance figures, but notes that net proceeds were used to regain compliance with NASDAQ stockholders' equity requirements.
Material Changes and Regulatory Status
The Company previously received notice from NASDAQ on April 12, 2017, regarding non-compliance with Listing Rule 5550(b)(1) (minimum stockholders' equity of $2.5 million) and Rule 5550(b)(2) (minimum market value of listed securities of $35 million). As of June 14, 2017, the Company believes it has regained compliance with Rule 5550(b)(1) due to the net proceeds from the offering. NASDAQ will continue to monitor ongoing compliance.
Outlook, Risks, and Contingencies
- Delisting Risk: If the Company fails to evidence compliance with NASDAQ Listing Rule 5550(b)(1) at the time of its next periodic report, its common stock may be subject to delisting.
- Conversion Limitations: Holders of Series B Preferred Stock are restricted from converting shares if it would result in beneficial ownership exceeding 4.99% of outstanding common stock.
- Management Commentary: The filing confirms the completion of the offering and the issuance of a press release (Exhibit 99.1) but provides no forward-looking financial guidance or operational outlook beyond the capital raise.
Investor Verification Checklist
- Verify the exact number of shares issued in the June 14, 2017 offering and the specific terms of the warrants issued.
- Confirm the Company's current stockholders' equity balance to ensure sustained compliance with NASDAQ Listing Rule 5550(b)(1).
- Review the full Certificate of Designation (Exhibit 3.1) for detailed liquidation preferences and conversion mechanics.
- Monitor the Company's next periodic report (10-Q or 10-K) for confirmation of continued NASDAQ compliance.